The Ministry of Health’s Food Safety Standards Authority of India has come out with quality and safety standards to regulate the standards and quality of health supplements, nutraceuticals, food (special dietary care, medicinal purpose, functional food and novel foods) and has sought public comments on the same. The effective date for the new rules is November 24.
Dr DBA Narayana, a leading scientist and industry expert told use of medicinal plants both as drugs and foods are now gaining importance. “The future of pharma and healthcare will focus considerably on natural based products. We will see functional foods and products for special dietary care, food for medicinal purpose, and novel foods that will target wellness to dominate the prescription landscape. This is an age of preventive healthcare and there students of botany and pharmacognosy who will now be able to part of the Indian herbal and food industry just as the government puts into effect the latest nutraceuticals regulation “
The pharma industry sees that specializations in plant medicine or pharmacognosy and botany to gain considerable traction as new career openings. Pharmacognosy deals with drugs obtained from plants or other natural sources are now a part of the pharmacy curriculum. In the wake of the immediate implementation of the regulations, there will be a need to scout for candidates in this specialisations, noted industry observers.
V Hariharan, chief executive officer and managing director, Phytotech Extracts and president, (HEMA), said that the sector has a promising future as it rides on India’s strengths in ancient herbal medicine and food supplements.
Increase in use of health and dietary formulations and with these new dedicated regulations not just pharmacy students but those armed with degrees in botany and pharmacognosy should be equipped with the necessary skills to carry out their responsibilities in this field. In recent FSSAI proposes new rules for health supplement mislabelling.
Other News
High-Value Medical Equipment: Customs Exemptions
High-Value Medical Equipment The Central Drugs Standard Control Organization (CDSCO) and the Central Board of Indirect Taxes & Customs have released a new circular, “F.No.401/40/2021-Cus.III,” detailing updated policies on the import of used high-end medical […]
Read MoreSEC – Special Expert Committee
The Central Drugs Standard Control Organization (CDSCO) has recently published an article titled “SEC – Special Expert Committee, Medical Devices”. Key highlights include the streamlined processes for CDSCO application evaluations, preparation and significance of briefing […]
Read More
ErlySign Oral Cancer Detection Technology Gets CDSCO Nod
ErlySign, a Nagpur-based biotech startup, has received approval from the Central Drugs Standard Control Organization (CDSCO) to conduct large-scale clinical trials for its novel oral cancer detection technology. The approval for ErlySign follows a rigorous […]
Read MoreAdditional Steps Announced by FDA to Modernize Clinical Trials
The U.S. Food and Drug Administration has made draft guidance available with updated recommendations for good clinical practices (GCPs), which are intended to modernize the clinical trial design and conduct while maintaining data integrity and […]
Read MoreAccreditation and Registration Numbers for Foreign Manufacturers Publication by PMDA
This article deals In accordance with the Pharmaceuticals and Medical Devices Act (PMD Act) of Japan, foreign businesses that wish to produce pharmaceuticals, quackery products, active pharmaceutical ingredients (APIs), or medical devices abroad and import […]
Read MoreBSI New Certification to Mitigate Antimicrobial Resistance Risk in Antibiotic Manufacturing
BSI, the business improvement and standards company, has developed a new certification to mitigate the risk of antimicrobial resistance (AMR) in antibiotic manufacturing. The certification, called the Minimized Risk of Antimicrobial Resistance (AMR) certification, will […]
Read More
TUV SUD Inspects IVD Medical Devices’ Cyber Security
The growing digital connectivity of medical infrastructure is resulting in complicated systems with a plethora of diverse interfaces that are potentially vulnerable to assault. The IVD requires producers to provide proof of cyber security before […]
Read More
TGA Supports MHRA’s New Regulations
The TGA made a commitment to support the MHRA‘s new Regulations worldwide recognition framework for pharmaceuticals. Following the UK’s exit from the European Union, a new international recognition framework for medicines has been developed specifically […]
Read More
